Literature DB >> 7572819

Atypical glandular cells of undetermined significance. Cytologic criteria to separate clinically significant from benign lesions.

S S Raab1, C Isacson, L J Layfield, J C Lenel, D D Slagel, P A Thomas.   

Abstract

Histologic follow-up of the cervical-vaginal smear diagnosis of atypical glandular cells of undetermined significance (AGUS) shows a broad spectrum of clinically significant (preneoplastic or neoplastic) and benign lesions. There are few statistical studies that have attempted to separate these AGUS categories based on select cytologic criteria. The authors retrospectively reviewed 116 AGUS without concurrent squamous dysplasia smears (66 clinically significant and 50 benign lesions), and used logistic regression analysis to identify the cytologic criteria of irregular nuclear membranes, atypical single cells, and decreased cytoplasm as useful in separating clinically significant from benign lesions. Using contingency tables, these criteria in combination had a sensitivity 29% and a specificity of 94% in the diagnosis of clinically significant lesions. If any single criterion was present, the sensitivity and specificity were 100% and 28%, respectively. In conclusion, by using key cytologic criteria, a percentage of benign AGUS lesions can be separated from clinically significant AGUS lesions.

Entities:  

Mesh:

Year:  1995        PMID: 7572819     DOI: 10.1093/ajcp/104.5.574

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  2 in total

1.  Atypical glandular cells in cervical smear during pregnancy and postpartum period.

Authors:  Kar Fai Tam
Journal:  Clin Med Res       Date:  2005-02

2.  Cytologic patterns of cervical adenocarcinomas with emphasis on factors associated with underdiagnosis.

Authors:  Rachel D Conrad; Angela H Liu; Nicolas Wentzensen; Roy R Zhang; S Terence Dunn; Sophia S Wang; Mark Schiffman; Michael A Gold; Joan L Walker; Rosemary E Zuna
Journal:  Cancer Cytopathol       Date:  2018-10-23       Impact factor: 5.284

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.